Patents by Inventor Gail K. Naughton

Gail K. Naughton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160256497
    Abstract: Compositions and methods for treating congestive heart failure are provided herein.
    Type: Application
    Filed: April 7, 2016
    Publication date: September 8, 2016
    Inventors: Michael Siani-Rose, Robert S. Kellar, Gail K. Naughton, Stuart K. Williams
  • Publication number: 20150315539
    Abstract: The invention provides a method for stimulating cell growth, differentiation and/or protein production in a cell. The method includes contacting a cell growth medium or fluid with a pulsed electromagnetic field (pEMF) and a low level laser (LLL). Contacting may be sequential or simultaneous.
    Type: Application
    Filed: May 5, 2015
    Publication date: November 5, 2015
    Inventors: Michael Villanueva, Gail K. Naughton
  • Publication number: 20150259739
    Abstract: The present invention provides methods for characterizing a skin sample of a subject as belonging to an age range by analyzing nucleic acid or protein molecules obtained from the subject. The methods include analyzing expression or mutations in epidermal samples, of one or more skin markers. The methods can include the use of a microarray to analyze gene or protein profiles from a sample and compare them with a known skin age index. Therapeutic and cosmetic formulations are also provided herein.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 17, 2015
    Inventors: Sherman H. Chang, Gail K. Naughton
  • Publication number: 20150246076
    Abstract: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.
    Type: Application
    Filed: May 13, 2015
    Publication date: September 3, 2015
    Inventors: Gail K. Naughton, Emmett Pinney
  • Patent number: 9034312
    Abstract: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.
    Type: Grant
    Filed: June 23, 2010
    Date of Patent: May 19, 2015
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Emmett Pinney
  • Patent number: 8852637
    Abstract: The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: October 7, 2014
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Emmett Pinney
  • Publication number: 20140271574
    Abstract: Compositions and methods for treating congestive heart failure are provided herein.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Michael Siani-Rose, Robert S. Kellar, Gail K. Naughton, Stuart K. Williams
  • Publication number: 20130344161
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Application
    Filed: August 27, 2013
    Publication date: December 26, 2013
    Applicant: Histogen, Inc.
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Patent number: 8535913
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: September 17, 2013
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Patent number: 8530415
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: September 10, 2013
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Patent number: 8524494
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: September 3, 2013
    Assignee: Histogen, Inc.
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Patent number: 8476231
    Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: July 2, 2013
    Assignee: Allergan, Inc.
    Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
  • Publication number: 20130064798
    Abstract: Compositions and methods for treating congestive heart failure are provided herein.
    Type: Application
    Filed: April 18, 2012
    Publication date: March 14, 2013
    Applicants: Arizona Board of Regents, Theregen, Inc.
    Inventors: Michael Siani-Rose, Robert S. Kellar, Gail K. Naughton, Stuart K. Williams
  • Patent number: 8361485
    Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.
    Type: Grant
    Filed: October 3, 2006
    Date of Patent: January 29, 2013
    Assignee: SkinMedica, Inc.
    Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
  • Publication number: 20120276062
    Abstract: Compositions and methods for treating ischemic tissue are provided herein.
    Type: Application
    Filed: February 23, 2012
    Publication date: November 1, 2012
    Applicant: Theregen, Inc.
    Inventors: Robert S. Kellar, Gail K. Naughton, Stuart K. Williams
  • Publication number: 20120230940
    Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Applicant: SkinMedica. Inc.
    Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
  • Patent number: 8257947
    Abstract: The present invention is directed to a method of producing compositions including embryonic proteins. The method includes culturing cells under hypoxic conditions on a biocompatible three-dimensional surface in vitro. The culturing method produces both soluble and non-soluble fractions, which may be used separately or in combination to obtain physiologically acceptable compositions useful in a variety of medical and therapeutic applications.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 4, 2012
    Inventors: Gail K. Naughton, Frank Ziegler, Mark Baumgartner, Kyle Nickey
  • Patent number: 8138147
    Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder.
    Type: Grant
    Filed: January 6, 2009
    Date of Patent: March 20, 2012
    Assignee: Skinmedica, Inc.
    Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
  • Patent number: 8128924
    Abstract: The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: March 6, 2012
    Assignee: Theregen, Inc.
    Inventors: Gail K. Naughton, Jonathan Noel Mansbridge, Robert Emmett Pinney, Joan Zeltinger
  • Publication number: 20110213470
    Abstract: The present invention relates to a method for promoting blood vessel formation in tissues and organs. In particular, the method relates to implantation or attachment of an engineered three-dimensional stromal tissue to promote endothelialization and angiogenesis in the heart and related tissues. The three-dimensional stromal tissue of the present invention may be used in a variety of applications including, but not limited to, promoting repair of and regeneration of damaged cardiac muscle, promoting vascularization and healing during cardiac surgery, promoting blood vessel formation at anastomosis sites, and promoting vascularization and repair of damaged skeletal muscle, smooth muscle or connective tissue.
    Type: Application
    Filed: December 29, 2010
    Publication date: September 1, 2011
    Applicant: Theregen, Inc.
    Inventors: Gail K. Naughton, Jonathan Noel Mansbridge, Robert Emmett Pinney, Joan Zeltinger